News

The NDA is supported by the results of two Phase III clinical trials evaluating the efficacy and safety of BDP Nasal HFA which showed improvement in nasal symptoms

The new patent named, ‘Neurotherapeutic compositions comprising a beta-lactam compound,’ includes compounds including clavulanic acid and moxalactam as a treatment for neurological disorders like, Alzheimer’s disease, anxiety, dementia,

Following the CE mark, CSD500 has got license to be marketed in 29 European countries and also in a number of non-European territories. Futura chief executive James Barder

Qnexa is an once-a-day, oral, controlled-release investigational drug candidate designed to decrease appetite, increase satiety and to address weight loss, type 2 diabetes and obstructive sleep apnea. The

The new organisation will run under the name Pharma KPO and will be incorporated in Singapore. Pharma KPO aims to take advantage of business opportunities by providing processes

Halozyme’s net income was $3.12m, or $0.03 per diluted share, compared to net loss of $12.15m, or $0.13 loss per diluted share, for the same period in 2010.

The increase in revenues primarily reflects gains in sales of the company’s products and services from its API, contract research and manufacturing and peptides synthesis businesses. Neuland Labs

In the study, ICR researchers have investigated DNA of women from 911 families with breast and ovarian cancer and compared differences in DNA with a control group of

P&G’s net earnings were $2.51bn for the fourth quarter ended 30 June 2011, compared to $2.19bn, for the same period in 2010. The company’s operating income was $3.29bn,